Cost-effectiveness of OKT3 induction therapy in cadaveric kidney transplantation.
Alsina
J
J
Bover
J
J
Grinyó
J M
JM
D002102:Cadaver; D003362:Cost-Benefit Analysis; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics*; D016030:Kidney Transplantation / Q000191:economics*; D016853:Muromonab-CD3 / Q000191:economics* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3